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Abstract: Curcumin, which is a potential antineuroinflammatory and neuroprotective compound,
exhibits poor bioavailability in brain cells due to its difficulty in crossing the blood–brain barrier
and its rapid metabolism during circulation, which decreases its efficacy in treating chronic
neuroinflammatory diseases in the central nervous system. The bioavailability and potential of
curcumin can be improved by using a nanodelivery system, which includes solid lipid nanoparticles.
Curcumin-loaded solid lipid nanoparticles (SLCN) were efficiently developed to have a particle
size of about 86 nm and do not exhibit any toxicity in the endothelial brain cells. Furthermore,
the curcumin-loaded solid lipid nanoparticles (SLCN) were studied to assess their efficacy in BV-2
microglial cells against LPS-induced neuroinflammation. The SLCN showed a higher inhibition
of nitric oxide (NO) production compared to conventional curcumin in a dose-dependent manner.
Similarly, the mRNA and proinflammatory cytokine levels were also reduced in a dose-dependent
manner when compared to those with free curcumin. Thus, SLCN could be a potential delivery
system for curcumin to treat microglia-mediated neuroinflammation.
Keywords: lipopolysaccharide; solid lipid nanoparticle; curcumin; antineuroinflammation; toxicity; SEM
1. Introduction
Neurodegenerative diseases, such as Parkinson’s disease (PD) or Alzheimer’s disease,
are age-related chronic illnesses that are characterized by the loss of neurons and activation of
microglia in brain cells [1,2]. Numerous studies have confirmed that neuroinflammation is a major
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factor of the degeneration in nigral neurons that are important characteristics of neurodegenerative
diseases [3]. Neuroinflammation leads to the activation of microglia and results in a higher production
of inflammatory markers, including nitric oxide, TNF-α, IL-1β, and IL-6 [4–7]. The suppression of
inflammatory markers using natural phytoextracts is in great demand for delaying neuroinflammation
and its related diseases.
Phytoextracts have been used for generations as traditional treatments for neurodegenerative
diseases [8–11]. Curcumin is a major bioactive compound that is found in turmeric powder and it is
used in traditional Indian and Chinese medicine due to its various health enhancing effects to treat
the inflammation associated with chronic diseases [12–16]. Furthermore, several in vitro and in vivo
mechanisms have determined for the antineuroinflammatory pathway of curcumin. Its efficacy is
still limited due to its low solubility, higher degradation by enzymes, lower absorption, and faster
elimination [17–21]. To improve the properties and biological activity, novel lipid-based delivery
vehicles are in greater demand [22], such as solid lipid nanoparticles (SLN).
SLN delivery systems are highly efficient delivery systems for phytocompounds with less
absorption and poorly bioavailability, such as curcumin, resveratrol etc. [23,24], due to their size
and higher stability. Recently, some researchers studied the curcumin-loaded SLN and observed
an enhancement in antitumor activity in vitro [25]. Furthermore, there was enhanced delivery of
curcumin-loaded SLN to cells without altering the integrity of the cellular junction [26]. SLN is in
greater demand compared to other nanodelivery systems due to its lower toxicity, ability to hold larger
lipophilic compounds, and higher bioavailability and solubility [27–29]. SLNs were also reported to
adhere to the endothelial cells of the blood–brain barrier (BBB) due to the surface adsorption of blood
proteins, such as apolipoproteins and can effectively shuttle drugs across BBB. This was proved in
a previous study, in which SLN was found to effectively shuttle the hydrophilic trypanocidal drug
diminazene across the BBB. Our previous research confirmed that the curcumin-loaded SLN increased
the bioavailability of curcumin in various organs, including the brain [30]. We further controlled the
release of orally administered curcumin by developing a modified chitosan coated SLN that enhanced
the bioavailability of curcumin [31–34]. To our knowledge, only a few studies have reported on
the antineuroinflammatory role of curcumin-loaded SLN against lipopolysaccharide (LPS)-induced
neuroinflammation in vitro and the molecular mechanism of its targeted pathways. Curcumin-loaded
SLN is an important means to deliver curcumin to microglial cells in a highly bioactive way. Thus,
the present study focused on the antineuroinflammatory mechanism of curcumin-loaded SLN (SLCN)
and its possible pathway in LPS-induced microglial cells.
2. Results
2.1. Physical Properties of SLN and SLCN
The particle size of SLN and SLCN, PDI and zeta potential are shown in Table 1. The particle size
of the SLCN was slightly higher compared to that of SLN, which means that the addition of curcumin
slightly increased the particle size of the SLCN. However, the particle size was found to be lower
than 100 nm and this could facilitate a higher bioavailability of curcumin to the cells. The EE and
LC of SLCN were 98.8% and 3%, respectively. A very high lipophilic behaviour of curcumin (log P
(Octanol/water partition coefficient) = 3.29) resulted in the higher intake of curcumin in the SLN solid
lipid core, which is made up of only lipids. There were no traces of curcumin after centrifugation for
EE and LC determination, with 98.8% of curcumin recovered from the SLN. The higher encapsulation
might be due to the ability of SLN to strongly accommodate the lipophilic curcumin. We were able to
confirm that curcumin has higher encapsulation efficiency in the SLN.
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Table 1. Physical properties of solid lipid nanoparticles (SLN) and curcumin-loaded solid lipid
nanoparticles (SLCN).
Formulations Particle size(nm) PDI
Zeta Potential
(mV) EE (%) LC (%)
SLN 83.16 ± 1.24 0.27 ± 0.02 −24.29 ± 1.66 - -
SLCN 86.60 ± 9.85 0.29 ± 0.02 −22.15 ± 1.32 98.8 ± 1.00 3.01
SLN: solid lipid nanoparticle; SLN: Curcumin loaded solid lipid nanoparticle; PDI: poly dispersity index; EE:
Encapsulation efficiency; and LC: Loading capacity.
2.2. Scanning Electron Microscopy (SEM) of SLCN
Furthermore, we confirmed the particle size of the dispersed SLCN in SEM and found that the
SLCN has a uniform particle size of less than 100 nm with a spherical shape (Figure 1).
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Figure 1. SEM micrograph of SLCN.
2.3. Cellular Toxicity Studies
The cell viability of the SLN and SCLN was compared between that in bEnd3 cells or NiH/3T3
cells, which is shown in Figure 2. The increase of about 100 µg/mL in the concentration of SLCN
in brain endothelial cells showed no cellular toxicity while the increase of about 500 µg/mL in the
NIH/3T3 cells showed no cellular toxicity for both SLN and SLCN.
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2.4. Effect of SLCN on NO Production in LPS-Stimulated BV2 Cells
Most of the naturally-derived candidates were reported to be safe with negligible/null toxicity.
Considering the potential of toxicity involved during formulation process in this study, we evaluated
the cytotoxic effects of SLCN, base curcumin and/or LPS in BV2 cells. The cells were pretreated
with SLCN (18 and 36 µg/mL) and base curcumin (36 µg/mL) for 1 h before the addition of LPS
(100 ng/mL). The incubation with LPS alone markedly increased the NO production in the BV2 cells
compared to the control (17.86 ± 0.98 µM; Figure 3A; ###p < 0.001 vs. untreated group). However,
the pretreatment with SLCN and base curcumin prevented this increase in the levels of NO production
in LPS-stimulated BV2 cells (Figure 3A; **p < 0.01 and ***p < 0.001 vs. LPS-treated group). Moreover,
SLCN resulted in a significantly greater inhibition of NO compared to base curcumin for the same
concentration (Figure 3A; $$p < 0.01 vs. SLCN-treated group). The cell viability was determined
using an MTT assay. According to the results of our study, both drugs and LPS treated cells exhibited
minimal/null toxic effects at the selected concentrations (Figure 3B).
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Figure 3. Effect of SLCN and base curcumin on NO production and cell viability in lipopolysaccharide
LPS-stimulated BV2 cells. BV2 cells were pretreated with the indicated concentrations (18 and
36 µg/mL) of SLCN and base curcumin (B.Cur) for 1 h before incubation with LPS (100 ng/mL)
for 24 h. Nitrite was measured using the Griess reaction (A). The cell viability was evaluated using the
MTT assay (B). Results are displayed as a percentage of untreated groups. ###p < 0.001, vs. untreated
group; **p < 0.01 and ***p < 0.001 vs. LPS-treated group; $$p < 0.01 vs. SLCN-treated group (one-way
ANOVA; n = 4).
2.5. SLCN Attenuated iNOS and COX -2 mRNA Expressions in LPS-Stimulated BV2 Cells
BV2 cells were induced with LPS (100 ng/mL) in the presence or absence of SLCN and base
curcumin at various concentrations (18 and 36 µg/mL, 36 µg/mL, espectively). LPS treatment
significantly increa ed the iNOS and COX-2 mRNA levels (###p < 0.001 vs. untreated g oup) but
pretreatment with SLCN and base curcumin at the indicated concentrations inhibited this LPS-induced
mRNA expression of i OS and COX-2 (Figure 4; **p < 0.01 and ***p < 0.001 v . LPS-tr ated group).
Further ore, SLCN improved the COX-2 mRNA level com ared to the base curcumin at the same
concentration (Figure 4; $p < 0.05 vs. SLCN-treated group). As discuss d earlie , this c n be
ttributed to the enhanced drug delivery potential of SLN. Thereby, as reported in arlier studies,
the relatively enhanced bioavailability of curcumin released from SLCN is likely responsible for its
higher suppression of iNOS nd COX-2 mRNA expr s ions co pared to its free form.
2.6. SLCN Inhibited the Production of Proinflammatory Cytokines in LPS-Induced BV2 Cells
RT-PCR results demonstrated elevated mRNA levels of these cytokines at 6 h after LPS treatment
(###p < 0.001 vs. untreated group). Pretreatment with SLCN significantly inhibited the LPS-induced
production of IL-1β, IL-6 and TNF-α (Figure 5; **p<0.01 and ***p<0.001 vs. LPS group). Furthermore,
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SLCN resulted in a greater reduction in the IL-6 and TNF-α mRNA levels compared to the base
curcumin at the same concentration (Figure 5; $p < 0.05 and $$p < 0.01 vs. SLCN-treated group). Thus,
our results indicate that SLCN inhibited the expression of proinflammatory mediators and associated
cytokines involved in the inflammatory process.
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Figure 4. SLCN attenuates iNOS and COX-2 mRNA levels in LPS-stimulated BV2 cells. BV2 cells
were pretreated with the indicated concentrations of SLCN and base curcumin for 1 h before being
incubated with LPS (100 ng/mL) for 6 h ( T-PCR). T tal RNA was prepared and analysed for iNOS
and COX-2 gene expression by RT-PCR. Quantification data are shown in the lower panel. ###p < 0.001
vs. untreated group; **p < 0.01 and ***i < 0.001 vs. LPS-treated group; $p < 0.05 vs. SLCN-treated group
(one-way ANOVA; n = 3).Molecules 2019, 24 FOR PEER REVIEW  6 
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Figure 5. SLCN decreases th production f proinfl mator cytokines. C lls were pretreated with
the indicated doses of SLCN and base curcumin for 1 h before LPS (100 ng/mL) treatment. The mRNA
levels of TNF-α, IL-1β, IL-6 and GAPDH were determined via RT-PCR. There was a representative
densitometry analysis of TNF-α, IL-1β and IL-6 com ared with GAPDH mRNA, respectively. ###E <
0.001 vs. untreated group; *p < 0.05, **p < 0.01 and ***p < 0.001 vs. LPS-treated group; $p < 0.05 and $$p
< 0.01 vs. SLCN-treated group (one-way ANOVA; n = 3).
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3. Discussion
The research aim of this study was to enhance the delivery of curcumin to the brain cells and to
study the possible antineuroinflammatory molecular mechanisms and neurotoxicological effects of
the curcumin loaded in SLN. SLCN created with different lipids had higher particle sizes [30], which
confirmed that the lipids in SLN play a significant role in determining the particle size of the SLCN.
The incorporation of curcumin also causes a slight increase in the PDI and the zeta potential of the
SLCN, with similar results observed in other studies [19,30]. The higher encapsulation might be due to
the ability of SLN to strongly accommodate the lipophilic curcumin. The results were consistent with
our previous studies [32]. Furthermore, the toxicity evaluation showed that a higher concentration of
curcumin loaded in SLN resulted in lower toxicity towards the brain endothelial cells. Similar results
were also shown in other studies with a higher concentration of SLCN, which showed no cellular
toxicity [34].
Furthermore, we studied the antineuroinflammatory mechanism of curcumin-loaded SLN in
LPS-induced BV2 microglial cells. The macrophage-like microglia are the resident innate immune cells
of central nervous system, which form the first-line defense to the CNS from the invading candidates
via several inflammatory signaling pathways [35]. The activation of microglial cells, either acute or
chronic, release several proinflammatory signals and cytotoxic factors, such as nitric oxide, cytokines
and ROS, to efficiently eradicate the invaded neuronal cells and safeguard the spread of disease
conditions. Despite this, the glial cells were also reported to facilitate neuroprotective properties to
regulate and resolve the inflammatory conditions by promoting several anti-inflammatory mediators
and cytoactive growth factors to repair the cells. Thus, it plays a dual role in both the destruction and
protection of neuronal cells. The homeostasis of the neuroinflammation is balanced by a feedback loop,
which limits the collateral damage inflicted by the inflammatory response. However, the imbalance
of this inflammatory homeostasis leads to an overproduction of NO, which subsequently cascades
several neuroinflammatory disorders. This is consistent with previous studies where the nanolipid
drug formulations exhibit better NO inhibitory activity in LPS-stimulated macrophages compared
to its free form. This is likely due to the enhanced drug delivery potential. Although most of the
naturally-derived candidates were reported to be safe with negligible/null toxicity, considering the
potential toxicity involved during the formulation process in this study, we evaluated the cytotoxic
effects of SLCN, base curcumin and/or LPS in BV2 cells. The cell viability was determined using
an MTT assay. According to the results of our study, both drugs and LPS treated cells exhibited
minimal/null toxic effects at the selected concentrations.
At the inflammation site, the activated microglial cells were reported to elevate the
proinflammatory mediators that are commonly generated by the inducible isoforms of NO synthase
(iNOS) and cyclooxygenase-2 (COX-2) enzymes. Several scientific evidences reported that the inducible
forms of iNOS and COX-2 facilitates the inflammatory conditions by the production of surplus NO and
prostaglandins (PG), respectively, which are highly cytotoxic. Interestingly, the induction of both iNOS
and COX 2 were bound to the transcriptional regulation. In our study, the relatively enhanced
bioavailability of curcumin released from SLCN is likely responsible for its higher suppression
of iNOS and COX-2 mRNA expression compared to its free from. The activated microglial cell
releases proinflammatory mediators (iNOS and COX 2) and further facilitates the transcriptional
cascades to elevate the supply of downstream proinflammatory cytokines, such as IL-1β, IL-6 and
TNF-α [36]. These released proinflammatory cytokines were reported to synergistically exacerbate
the inflammatory milieu together with NO and PGs by activating the neighboring glial cells and
astrocytes. Thus, they play pivotal roles in microglia-mediated inflammation. It was previously
reported that LPS induction substantially elevates the upsurge of proinflammatory cytokines (IL-1β,
IL-6 and TNF-α) via the MAPK signaling pathway in BV-2 glial cells. Relatively, the candidates
that suppress the expression of these proinflammatory cytokines were reported to show substantial
neuroprotective effects against several inflammatory induced neurodegenerative disorders [37]. This is
consistent with previous study findings where the active drug candidates loaded into nanoparticles
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resulted in substantial suppression of proinflammatory cytokines and exhibited relatively higher
antineuroinflammatory effects than their free forms. Another recent study showed that curcumin
exerts an antiinflammatory effect by downregulating the PI3k/Akt signaling pathway and NF-κB
(nuclear factor kappa-light-chain-enhancer of activated B cells) protein levels [38]. This could possibly
be attributed to the downregulation of mRNA expression of proinflammatory cytokines by SLCN
in our current study. It is also noteworthy that a previous study report states that SLN itself does
not impact the viability and inflammatory effects of macrophages [39]. Thus, our results indicate
that curcumin-loaded SLCN inhibited the expression of proinflammatory mediators and associated
cytokines involved in the inflammatory process. The possible antiinflammatory mechanism of the
SLCN in LPS that stimulated BV-2 microglial cells is depicted in Figure 6.Molecules 2019, 24 FOR PEER REVIEW  8 
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4. Materials and Methods
4.1. Materials
Curcumin (C. longa. Linn) was obtained from TCI Co., Ltd. (Tokyo, Japan), Lipopolysaccharide
(LPS, E. coli 0111:B4), dimethyl sulfoxide (DMSO), sulfanilamide, N-(1-naphthyl)-ethylenediamine
dihydrochloride 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and Tween-20
were purchased from Sigma–Aldrich (St. Louis, MO, USA). Foetal bovine serum (FBS), Dulbecco’s
Modified Eagle Medium (DMEM), penicillin-streptomycin (P-S), trypsin/EDTA (TE), TRIzol and other
cell culture plates were obtained from Gibco-BRL (Rockville, MD, USA).
4.2. Solid Lipid Curcumin Nanoparticle Formulati n and Optimization
The formulation of curcumin-loaded SLCN was prepared using high shear homogenization and
ultrasonication techniques, with the different lipid formulations of SLCN used as shown in Table 1.
This was conducted according to the modified method of Ramalingam and K Briefly, different
r ti s of precirol, palmitic acid and gelucire were heated to 85 ◦C to complete s lubilize the lipid.
After the lipid was c mpletely melte , curcumin was added to the lipid phas . The aqueous phase
containing Tween 80 w s added to the lipid phase and homogenized using Ultra- Turrax homogenizer
(IKA-Werke, Staufen, Germany) at around 11,000 rpm for 5 min. The curcumin or free preemulsion
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was further ultrasonicated for 5 min using a probe sonicator (Vibracell VCX130; Sonics, Newtown,
CT, USA). The obtained SLCN was cooled for 30 min and lyophilized before being stored at 4 ◦C for
further experiments.
4.3. Particle Size, Zeta Potential and Polydispersity Index
The particle size, zeta potential and polydispersity index (PDI) of SLN and SLCN was measured
using an ELSZ-1000 zeta potential and particle size analyser (Photal OTSUKA Electronics, Tokyo,
Japan). The SLCN efficiency of EE and LC was measured according to the modified method as
described by Ramalingam and Ko [30]. For SEM, 10 µL of the 0.1 mg/mL SLN sample was added to the
silica grid, dried, sputter coated with platinum and further used for HR-SEM analysis (High Resolution
Field Emission Scanning Electron Microscope JSM-7610F, JEOL Ltd., Akishima, Tokyo, Japan).
4.4. Cell Toxicity Studies
Cellular toxicity studies of SLCN and SLN were carried out and compared using two different
cells, such as NIH/3T3 and brain endothelial cells, using an MTT assay.
4.5. Cell Culture, NO Release Assay and Cell Viability
BV2 cells were cultured in DMEM supplemented with 5% FBS and 100 U/mL P-S before being
maintained in a humidified incubator in an 5% CO2 atmosphere. In all experiments, cells were seeded
at a density of 5 × 105 cells/mL and were pretreated for 1 h with the indicated concentrations of
curcumin-loaded solid lipid nanoparticles (SLCN) and base curcumin before being incubated in a
medium containing LPS (100 ng/mL). The LPS-induced release of NO in the culture medium was
determined and the cell viability of the cultured cells was measured. Briefly, the seeded cells were
treated with different concentrations of SLCN (18 and 36 µg/mL) and 36 µg/mL of base curcumin,
which was followed by incubation with LPS for 24 h. After incubation with LPS for 24 h, 50 µL
of each culture medium was mixed with 50 µL of Griess reagent. Nitrite levels were determined
using a microplate reader at 540 nm (Tecan Trading AG, Switzerland) and nitrite concentrations were
calculated by reference to a standard curve generated by the known concentrations of sodium nitrite.
The cell viability was measured by adding 0.5 mg/mL of MTT to each well. After incubation for
another 4 h at 37 ◦C and 5% CO2, the medium was removed from each well and the formazan crystals
that formed were dissolved in DMSO. The absorbance was determined at 540 nm using a microplate
reader (Tecan Trading AG).
4.6. Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Viability
BV2 microglia cells were plated overnight in 6-well culture plates and were pretreated for 1 h
with the indicated concentrations of SLCN (18 and 36 µg/mL) and base curcumin (36 µg/mL) before
incubation in a medium containing LPS (100 ng/mL). The total RNA was extracted using TRIZOL
(Invitrogen). RNA (1 µg) was reverse-transcribed using ReverTra Ace-α kit (Toyobo, Osaka, Japan)
according to the manufacturer’s instructions. The inducible nitric oxide synthase, cyclooxygenase
type 2 (COX-2), tumour necrosis factor-alpha (TNF-α), interleukin 1β (IL-1β), IL-6 and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) genes were amplified from the cDNA via polymerase chain
reaction (PCR). cDNA was amplified by PCR using the specific primers mentioned in Table 2. PCR was
performed using an initial step of denaturation (5 min at 94 ◦C), 20–27 cycles of amplification (94 ◦C
for 30 s, 54–58 ◦C for 1 min and 72 ◦C for 1 min) and an extension (72 ◦C for 5 min). PCR products
were analysed on 1.5% agarose gels with EtBr stained. The mRNA of GAPDH served as an internal
control for sample loading and mRNA integrity. The band intensity was quantified via a densitometry
analysis using multi-gauge software V3.1 (Fujifilm, Tokyo, Japan).
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Table 2. Primer sets used for RT-PCR.
Gene Primer Sequence Size (bp) Accession
iNOS
Forward 5′-CTTGCAAGTCCAAGTCTTGC-3′
369 NM_010927Reverse 5′-GTATGTGTCTGCAGATGTGCTG-3′
COX-2
Forward 5′-ACATCCCTGAGAACCTGCAGT-3′
414 NM_011198Reverse 5′-CCAGGAGGATGGAGTTGTTGT-3′
IL-1β
Forward 5′-CATATGAGCTGAAAGCTCTCCA-3′
385 NM_008361Reverse 5′-GACACAGATTCCATGGTGAAGTC-3′
IL-6
Forward 5′-GGAGGCTTAATTACACATGTT-3′
435 NM_031168Reverse 5’-TGATTTCAAAGATGAATTGGAT-3‘
TNF-α
Forward 5′-TTCGAGTGACAAGCCTGTAGC-3′
390 NM_013693Reverse 5′-AGATTGACCTCAGCGCTGAGT-3′
GAPDH
Forward 5′-CCAGTATGACTCCACTCACG-3′
378 GU214026Reverse 5′-CCTTCCACAATGCCAAAGTT-3′
4.7. Statistical Analysis
The values given are means ± S.E.M. of at least three separate experiments conducted in triplicate.
The comparisons between groups were analyzed using a one-way analysis of variance (ANOVA)
followed by Tukey’s multiple comparison test using software GraphPad Prism V6.01 (GraphPad
Software Inc., San Diego, CA, USA)
5. Conclusions
The antineuroinflammatory potential of curcumin-loaded solid lipid nanoparticles was studied
in this work. SLCN effectively and dose-dependently reduced the NO release in LPS-induced BV-2
microglial cells, which potentially occurred via the regulation of proinflammatory cytokines and
associated mediators. Interestingly, the curcumin released from SLN exhibited a relatively higher
inflammation-suppressive activity compared to its free form, which can be likely attributed towards
the sustained release and enhanced bioavailability of SLN. Thus, further studies on fabrication and
functionalization of SLCN can effectively pave the way to develop novel drug candidates to treat
inflammation-mediated neurodegenerative disorders.
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